论文部分内容阅读
目的:观察解毒舒肝片对HBe Ag阴性慢性乙肝患者的治疗作用。方法:将60例HBe Ag阴性慢性乙肝患者随机分为治疗组和对照组,治疗组32例给予解毒舒肝片,对照组28例给予阿拓莫兰片、五酯滴丸。在0周、12周、24周检测HBV-DNA、ALT、AST水平及进行安全性评价。结果:两组在12周及24周ALT、AST均较治疗前明显下降(p<0.05)。治疗组在12周及24周HBV-DNA较治疗前明显下降(p<0.05),24周时HBV-DNA下降较对照组明显(p<0.05)。治疗组24周HBV-DNA阴转率为28.12%,对照组为7.14%。结论:解毒舒肝片能够在一定程度上抑制HBe Ag阴性慢性乙肝患者HBVDNA复制,促进肝功能恢复,具有治疗HBe Ag阴性慢性乙肝作用,且安全性良好。
Objective: To observe the therapeutic effect of Jiedu Shugan Tablet on HBeAg-negative chronic hepatitis B patients. Methods: Sixty HBeAg-negative chronic hepatitis B patients were randomly divided into treatment group and control group. 32 cases in treatment group were given detoxification Shugan tablets, while 28 cases in control group were given addonolan tablets and pentosan drops. The levels of HBV DNA, ALT and AST were measured at 0 week, 12 weeks and 24 weeks and the safety evaluation was performed. Results: The ALT and AST in both groups decreased significantly at 12 and 24 weeks (p <0.05). HBV-DNA in treatment group decreased significantly at 12 weeks and 24 weeks (p <0.05), and decreased at 24 weeks compared with that in control group (p <0.05). The negative conversion rate of HBV-DNA in the treatment group was 28.12% at 24 weeks and 7.14% in the control group. Conclusion: Jiedu Shugan tablet can inhibit the HBVDNA replication in patients with HBeAg-negative chronic hepatitis B to a certain extent, promote the recovery of liver function, have the effect of treating HBeAg-negative chronic hepatitis B and have good safety.